{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:45:57Z","timestamp":1791841557808,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The impact of sodium\u2013glucose linked transporter-2 inhibitors (SGLT2i) on urinary tract infection (UTI) risk remains uncertain and may be dose-dependent. No prior studies have evaluated their effect in patients with urinary diversion after cystectomy. This study evaluated the association between SGLT2i use and UTI in patients with diabetes mellitus (DM) after cystectomy and ileal urinary diversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective single-center cohort study including all patients with DM who underwent cystectomy with ileal urinary diversion between March 1996 and November 2023. Primary outcome was UTI occurrence, assessed by incidence rate and infection-free survival (IFS). Secondary outcomes included asymptomatic bacteriuria and glucosuria. UTI incidence rate was compared using Poisson\u00a0regression. IFS was evaluated using Kaplan\u2013Meier curves, log-rank test and Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 123 included patients with DM and ileal urinary diversion, 18 (14.6%) received SGLT2i therapy. Median follow-up was 35\u00a0months (IQR 12\u201383). Overall, 121 UTI were documented, 6 (5.0%) in patients with and 115 (95.0%) without SGLT2i treatment, corresponding to incidence rates of 0.206 vs. 0.210 UTI\/patient\/year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.959). Median IFS was 9\u00a0months (IQR 3\u201331) in the SGLT2i and 17\u00a0months (IQR 5\u201374) in the non-SGLT2i group, with no significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.489).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cohort, SGLT2i therapy was not associated with an increased risk of UTI in patients with DM and ileal urinary diversion after cystectomy. These findings suggest no evident signal for increased infection risk; however, prospective studies are warranted to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05175-4","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:19:31Z","timestamp":1778318371000},"page":"4169-4177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of SGLT2 inhibitors on urinary tract infections in patients with diabetes mellitus and ileal urinary diversion: a retrospective cohort study"],"prefix":"10.1007","volume":"58","author":[{"given":"Nicolas","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Hischier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Dorin","family":"Vartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Schneidewind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"R\u00f6thlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"5175_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"DR Whiting","year":"2011","unstructured":"Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311\u2013321. https:\/\/doi.org\/10.1016\/j.diabres.2011.10.029","journal-title":"Diabetes Res Clin Pract"},{"key":"5175_CR2","unstructured":"Department of Health and Human Services Food and Drug Administration. Guidance for industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008:77724\u20135."},{"key":"5175_CR3","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012."},{"key":"5175_CR4","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2024","unstructured":"Pharmacologic Approaches to Glycemic Treatment (2024) Standards of Care in Diabetes\u20142024. Diabetes Care 47:S158\u2013S178. https:\/\/doi.org\/10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"5175_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.24920\/J1001-9242.2007.003","volume":"32","author":"Y Yang","year":"2017","unstructured":"Yang Y, Pan H, Wang B, Chen S, Zhu H, Yang Y (2017) Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Chin Med Sci J 32:22\u201327. https:\/\/doi.org\/10.24920\/J1001-9242.2007.003","journal-title":"Chin Med Sci J"},{"key":"5175_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12:447\u2013461. https:\/\/doi.org\/10.1016\/S2213-8587(24)00102-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5175_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","volume":"5","author":"S Kalra","year":"2014","unstructured":"Kalra S (2014) Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 5:355\u2013366. https:\/\/doi.org\/10.1007\/s13300-014-0089-4","journal-title":"Diabetes Ther"},{"key":"5175_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19:348\u2013355. https:\/\/doi.org\/10.1111\/dom.12825","journal-title":"Diabetes Obes Metab"},{"key":"5175_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55:503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0","journal-title":"Acta Diabetol"},{"key":"5175_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-025-04393-7","volume":"90","author":"BT Yoosuf","year":"2025","unstructured":"Yoosuf BT, Kt MF, D PS, Saini A, Garg P, Medenica S et al (2025) Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: a meta-analysis of randomised controlled trials and disproportionality analysis using FAERS. Endocrine 90:439\u2013452. https:\/\/doi.org\/10.1007\/s12020-025-04393-7","journal-title":"Endocrine"},{"key":"5175_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00125-006-0570-3","volume":"50","author":"T Benfield","year":"2007","unstructured":"Benfield T, Jensen JS, Nordestgaard BG (2007) Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 50:549\u2013554. https:\/\/doi.org\/10.1007\/s00125-006-0570-3","journal-title":"Diabetologia"},{"key":"5175_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/diacare.26.2.510","volume":"26","author":"BR Shah","year":"2003","unstructured":"Shah BR, Hux JE (2003) Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26:510\u2013513. https:\/\/doi.org\/10.2337\/diacare.26.2.510","journal-title":"Diabetes Care"},{"key":"5175_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247628","volume":"13","author":"T Sorescu","year":"2024","unstructured":"Sorescu T, Cosnita A, Braha A, Timar R, Timar B, Licker M et al (2024) Predictive factors for urinary tract infections in patients with type 2 diabetes. J Clin Med 13:13. https:\/\/doi.org\/10.3390\/jcm13247628","journal-title":"J Clin Med"},{"key":"5175_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12020-023-03469-6","volume":"82","author":"M Dai","year":"2023","unstructured":"Dai M, Hua S, Yang J, Geng D, Li W, Hu S et al (2023) Incidence and risk factors of asymptomatic bacteriuria in patients with type 2 diabetes mellitus: a meta-analysis. Endocrine 82:263\u2013281. https:\/\/doi.org\/10.1007\/s12020-023-03469-6","journal-title":"Endocrine"},{"key":"5175_CR15","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa021042","volume":"347","author":"GKM Harding","year":"2002","unstructured":"Harding GKM, Zhanel GG, Nicolle LE, Cheang M (2002) Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 347:1576\u20131583. https:\/\/doi.org\/10.1056\/NEJMoa021042","journal-title":"N Engl J Med"},{"key":"5175_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","volume":"25","author":"LS Yang","year":"2016","unstructured":"Yang LS, Shan BL, Shan LL, Chin P, Murray S, Ahmadi N et al (2016) A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol 25:281\u2013297. https:\/\/doi.org\/10.1016\/j.suronc.2016.05.027","journal-title":"Surg Oncol"},{"key":"5175_CR17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/j.1464-410X.2007.07366.x","volume":"101","author":"F Suriano","year":"2008","unstructured":"Suriano F, Gallucci M, Flammia GP, Musco S, Alcini A, Imbalzano G et al (2008) Bacteriuria in patients with an orthotopic ileal neobladder: urinary tract infection or asymptomatic bacteriuria? BJU Int 101:1576\u20131579. https:\/\/doi.org\/10.1111\/j.1464-410X.2007.07366.x","journal-title":"BJU Int"},{"key":"5175_CR18","unstructured":"Bonkat G, Kranz J, Cai T, Geerlings SE, K\u00f6ves B, Pilatz A, et al. EAU Guidelines on Urological Infections. EAU Guidelines Edn Presented at the EAU Annual Congress Madrid, Spain 2025 n.d."},{"key":"5175_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00345-004-0432-x","volume":"22","author":"B Wullt","year":"2004","unstructured":"Wullt B, Agace W, Mansson W (2004) Bladder, bowel and bugs - bacteriuria in patients with intestinal urinary diversion. World J Urol 22:186\u2013195. https:\/\/doi.org\/10.1007\/s00345-004-0432-x","journal-title":"World J Urol"},{"key":"5175_CR20","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1097\/01.ju.0000067909.98836.91","volume":"169","author":"DP Wood","year":"2003","unstructured":"Wood DP, Bianco FJ, Pontes JE, Heath MA, DaJusta D (2003) Incidence and significance of positive urine cultures in patients with an orthotopic neobladder. J Urol 169:2196\u20132199. https:\/\/doi.org\/10.1097\/01.ju.0000067909.98836.91","journal-title":"J Urol"},{"key":"5175_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00345-019-02964-8","volume":"38","author":"LG Qu","year":"2020","unstructured":"Qu LG, Adam A, Ranasinghe W, Lawrentschuk N (2020) Systematic review: bacterial colonisation of conduits and neobladders\u2014when to test, watch, and treat. World J Urol 38:1413\u20131422. https:\/\/doi.org\/10.1007\/s00345-019-02964-8","journal-title":"World J Urol"},{"key":"5175_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00345-018-2181-2","volume":"36","author":"TG Clifford","year":"2018","unstructured":"Clifford TG, Katebian B, Van Horn CM, Bazargani ST, Cai J, Miranda G et al (2018) Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients. World J Urol 36:775\u2013781. https:\/\/doi.org\/10.1007\/s00345-018-2181-2","journal-title":"World J Urol"},{"key":"5175_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2018.03.042","volume":"116","author":"R Mano","year":"2018","unstructured":"Mano R, Goldberg H, Stabholz Y, Hazan D, Margel D, Kedar D et al (2018) Urinary tract infections after urinary diversion\u2014different occurrence patterns in patients with ileal conduit and orthotopic neobladder. Urology 116:87\u201392. https:\/\/doi.org\/10.1016\/j.urology.2018.03.042","journal-title":"Urology"},{"key":"5175_CR24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1464-410X.2009.08909.x","volume":"105","author":"H Thulin","year":"2010","unstructured":"Thulin H, Steineck G, Kreicbergs U, Onel\u00f6v E, Ahlstrand C, Carringer M et al (2010) Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. BJU Int 105:1107\u20131117. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08909.x","journal-title":"BJU Int"},{"key":"5175_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.urology.2016.03.049","volume":"94","author":"WP Parker","year":"2016","unstructured":"Parker WP, Toussi A, Tollefson MK, Frank I, Thompson RH, Zaid HB et al (2016) Risk factors and microbial distribution of urinary tract infections following radical cystectomy. Urology 94:96\u2013101. https:\/\/doi.org\/10.1016\/j.urology.2016.03.049","journal-title":"Urology"},{"key":"5175_CR26","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"Classification and Diagnosis of Diabetes","year":"2022","unstructured":"Classification and Diagnosis of Diabetes (2022) Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45:S17-38. https:\/\/doi.org\/10.2337\/dc22-S002","journal-title":"Diabetes Care"},{"key":"5175_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2016.04.071","volume":"196","author":"SM Lenherr","year":"2016","unstructured":"Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM et al (2016) Glycemic control and urinary tract infections in women with Type 1 Diabetes: results from the DCCT\/EDIC. J Urol 196:1129\u20131135. https:\/\/doi.org\/10.1016\/j.juro.2016.04.071","journal-title":"J Urol"},{"key":"5175_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6573215","volume":"2016","author":"M Sewify","year":"2016","unstructured":"Sewify M, Nair S, Warsame S, Murad M, Alhubail A, Behbehani K et al (2016) Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycemia in Kuwait. J Diabetes Res 2016:6573215. https:\/\/doi.org\/10.1155\/2016\/6573215","journal-title":"J Diabetes Res"},{"key":"5175_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"5175_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05175-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:01:47Z","timestamp":1791838907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05175-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5175"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05175-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board (IRB\/KEK-BE 2016\u201400660). The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}